Hamilton, Bermuda – 25 June 2019 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced webcast for Sunosi Investor Update.  The filing stated:

DUBLIN, June 25, 2019 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Tuesday, July 2, 2019 at 4:30 p.m. EDT/9:30 p.m. IST to provide investors with an update on Sunosi™ (solriamfetol), which was approved by the U.S. Food and Drug Administration on March 20, 2019 to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved to treat excessive daytime sleepiness in adults living with narcolepsy or OSA. Beginning early July, Sunosi will be commercially available in the U.S. following the recent scheduling decision by the U.S. Drug Enforcement Agency.

The investor webcast will include an overview of narcolepsy and OSA from invited physician experts as well as a Sunosi overview from the company’s senior management.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company’s website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. As a leader in sleep medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical discoveries into novel medicines. Jazz Pharmaceuticals markets Sunosi^TM (solriamfetol), Xyrem® (sodium oxybate) oral solution, Defitelio® (defibrotide sodium), Erwinaze® (asparaginase Erwinia chrysanthemi) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Defitelio® (defibrotide), Erwinase® and Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S. For country-specific product information, please visit www.jazzpharmaceuticals.com/medicines. For more information, please visit www.jazzpharmaceuticals.comand follow us on Twitter at @JazzPharma.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the expected timing of commercial availability of Sunosi in the U.S. and other statements that are not historical facts. These forward-looking statements are based on the company'scurrent plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties,which

include, without limitation, risks and uncertainties associated with: delays or problems in the supply or manufacture of Sunosi; complying with applicable U.S. regulatory requirements; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 and future filings and reports by the company. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the company on its website or otherwise. The company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Jazz Pharmaceuticals Contacts:

Investors:

Kathee Littrell

Vice President, Investor Relations Ireland, +353 1 634 7887

U.S., +1 650 496 2717

Media:

Jacqueline Kirby

Vice President, Corporate Affairs & Government Relations Ireland, +353 1 697 2141

U.S., +1 215 867 4910